Neurological Surgery 脳神経外科49巻3号

2021年05月発行

特集 グリオーマ—現在の常識と近未来のスタンダード Ⅴ各種グリオーマの集学的治療戦略

高齢者グリオーマ

著者： 山崎文之¹ 高安武志¹ 花谷亮典²

所属機関： ¹広島大学病院脳神経外科 ²鹿児島大学病院脳神経外科

ページ範囲：P.647 - P.659

Point
・臓器機能や認知機能の低下に対して高齢者総合機能評価（CGA）を行い，治療強度を適切に調整する．
・脆弱（unfit）の高齢者患者に対して寡分割放射線照射やテモゾロミド単独療法などが開発され，非劣性が示された．
・高齢者グリオーマに対するてんかん治療では，臓器機能や認知機能と薬物代謝に配慮が必要である．

参考文献

1）Wick A, et al：Glioblastoma in elderly patients：solid conclusions built on shifting sand? Neuro Oncol 20：174-183, 2018

2）Ostrom QT, et al：CBTRUS statistical report：Primary brain and central nervous system tumors diagnosed in the United States in 2006-2010. Neuro Oncol 15（Suppl 2）：ii1-ii56, 2013

3）Brain Tumor Registry of Japan（2005-2008）. Neurol Med Chir（Tokyo）57（Suppl 1）：9-102, 2017

4）Repetto L, et al：Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients：an Italian Group for Geriatric Oncology Study. J Clin Oncol 20：494-502, 2002

5）Lombardi G, et al：Validation of the comprehensive geriatric assessment as a predictor of mortality in elderly glioblastoma patients. Cancers（Basel）11：1509, 2019

6）Dobran M, et al：Characteristics of treatment and outcome in elderly patients with brain glioblastoma：a retrospective analysis of case series. Acta Clin Croat 58：221-228, 2019

7）Lacroix M, et al：A multivariate analysis of 416 patients with glioblastoma multiforme：prognosis, extent of resection, and survival. J Neurosurg 95：190-198, 2001

8）Lamborn KR, et al：Prognostic factors for survival of patients with glioblastoma：recursive partitioning analysis. Neuro Oncol 6：227-235, 2004

9）Sanai N, Berger MS：Glioma extent of resection and its impact on patient outcome. Neurosurgery 62：753-764；discussion 764-766, 2008

10）Kuhnt D, et al：Correlation of the extent of tumor volume resection and patient survival in surgery of glioblastoma multiforme with high-field intraoperative MRI guidance. Neuro Oncol 13：1339-1348, 2011

11）Sanai N, et al：An extent of resection threshold for newly diagnosed glioblastomas. J Neurosurg 115：3-8, 2011

12）Orringer D, et al：Extent of resection in patients with glioblastoma：limiting factors, perception of resectability, and effect on survival. J Neurosurg 117：851-859, 2012

13）Oszvald A, et al：Glioblastoma therapy in the elderly and the importance of the extent of resection regardless of age. J Neurosurg 116：357-364, 2012

14）Babu R, et al：Glioblastoma in the elderly：the effect of aggressive and modern therapies on survival. J Neurosurg 124：998-1007, 2016

15）Keime-Guibert F, et al；Association of French-Speaking Neuro-Oncologists：Radiotherapy for glioblastoma in the elderly. N Engl J Med 356：1527-1535, 2007

16）Roa W, et al：Abbreviated course of radiation therapy in older patients with glioblastoma multiforme：a prospective randomized clinical trial. J Clin Oncol 22：1583-1588, 2004

17）Wick W, et al；NOA-08 Study Group of Neuro-oncology Working Group（NOA）of German Cancer Society：Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly：the NOA-08 randomised, phase 3 trial. Lancet Oncol 13：707-715, 2012

18）Malmström A, et al；Nordic Clinical Brain Tumour Study Group（NCBTSG）：Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma：the Nordic randomised, phase 3 trial. Lancet Oncol 13：916-926, 2012

19）Roa W, et al：International Atomic Energy Agency randomized phase Ⅲ study of radiation therapy in elderly and/or frail patients with newly diagnosed glioblastoma multiforme. J Clin Oncol 33：4145-4150, 2015

20）Perry JR, et al；Trial Investigators：Short-course radiation plus temozolomide in elderly patients with glioblastoma. N Engl J Med 376：1027-1037, 2017

21）Stupp R, et al；European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups；National Cancer Institute of Canada Clinical Trials Group：Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352：987-996, 2005

22）Blumenthal DT, et al：Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma：a secondary analysis of EORTC and NRG Oncology/RTOG. Neuro Oncol 19：1119-1126, 2017

23）Gramatzki D, et al：Limited role for extended maintenance temozolomide for newly diagnosed glioblastoma. Neurology 88：1422-1430, 2017

24）Chinot OL, et al：Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 370：709-722, 2014

25）Davies J, et al：Survival in elderly glioblastoma patients treated with bevacizumab-based regimens in the United States. Neurooncol Pract 5：251-261, 2018

26）Matsuda KI, et al：Treatment outcomes of hypofractionated radiotherapy combined with temozolomide followed by bevacizumab salvage therapy in glioblastoma patients aged ＞ 75 years. Int J Clin Oncol 23：820-825, 2018

27）Ohno M, et al：Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged ≥75 years. Radiat Oncol 14：200, 2019

28）Wirsching HG, et al：Bevacizumab plus hypofractionated radiotherapy versus radiotherapy alone in elderly patients with glioblastoma：the randomized, open-label, phase Ⅱ ARTE trial. Ann Oncol 29：1423-1430, 2018

29）Hata N, et al：First-line bevacizumab contributes to survival improvement in glioblastoma patients complementary to temozolomide. J Neurooncol 146：451-458, 2020

system user study. World J Surg Oncol 13：316, 2015

31）Stupp R, et al：NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma：a randomised phase Ⅲ trial of a novel treatment modality. Eur J Cancer 48：2192-2202, 2012

32）Stupp R, et al：Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma：a randomized clinical trial. JAMA 318：2306-2316, 2017

33）Shi W, et al：Global post-marketing safety surveillance of Tumor Treating Fields（TTFields）in patients with high-grade glioma in clinical practice. J Neurooncol 148：489-500, 2020

34）Pignatti F, et al；European Organization for Research and Treatment of Cancer Brain Tumor Cooperative Group；European Organization for Research and Treatment of Cancer Radiotherapy Cooperative Group：Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol 20：2076-2084, 2002

35）Daniels TB, et al：Validation of EORTC prognostic factors for adults with low-grade glioma：a report using intergroup 86-72-51. Int J Radiat Oncol Biol Phys 81：218-224, 2011

36）Turcan S, et al：IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 483（7390）：479-483, 2012

37）Kumthekar P, et al：Prognosis of older patients with low-grade glioma：a retrospective study. Integr Cancer Sci Ther 4：10.15761, 2017

38）Capelle L, et al；French Réseau d'Étude des Gliomes：Spontaneous and therapeutic prognostic factors in adult hemispheric World Health Organization Grade Ⅱ gliomas：a series of 1097 cases：clinical article. J Neurosurg 118：1157-1168, 2013

39）Kaloshi G, et al：Supratentorial low-grade gliomas in older patients. Neurology 73：2093-2098, 2009

40）Schomas DA, et al：Low-grade gliomas in older patients：long-term follow-up from Mayo Clinic. Cancer 115：3969-3978, 2009

41）Karim AB, et al：A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma：European Organization for Research and Treatment of Cancer（EORTC）Study 22844. Int J Radiat Oncol Biol Phys 36：549-556, 1996

42）Piotrowski AF, Blakeley J：Clinical management of seizures in patients with low-grade glioma. Semin Radiat Oncol 25：219-224, 2015

43）Berntsson SG, et al：Glioma-related seizures in relation to histopathological subtypes：a report from the glioma international case-control study. J Neurol 265：1432-1442, 2018

44）Samudra N, et al：Seizures in glioma patients：an overview of incidence, etiology, and therapies. J Neurol Sci 404：80-85, 2019

45）Hanaya R, Arita K：The new antiepileptic drugs：their neuropharmacology and clinical indications. Neurol Med Chir（Tokyo）56：205-220, 2016

46）Vecht C, et al：Seizures and anticonvulsants in brain tumours：frequency, mechanisms and anti-epileptic management. Curr Pharm Des 23：6464-6487, 2017

47）Koekkoek JA, et al：Seizure reduction in a low-grade glioma：more than a beneficial side effect of temozolomide. J Neurol Neurosurg Psychiatry 86：366-373, 2015

48）Ertürk Çetin Ö, et al：Epilepsy-related brain tumors. Seizure 44：93-97, 2017

49）Izumoto S, et al：Seizures and tumor progression in glioma patients with uncontrollable epilepsy treated with perampanel. Anticancer Res 38：4361-4366, 2018

50）Lange F, et al：AMPA receptor antagonist perampanel affects glioblastoma cell growth and glutamate release in vitro. PLoS One 14：e0211644, 2019